Boston Scientific Express Stent Potentially Threatened By Medinol Lawsuit
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's strategy to rely on its internally developed Express coronary stent platform as a viable alternative to a troubled relationship with stent partner Medinol may be jeopardized by the Israeli firm's April 5 lawsuit alleging that the Express R&D initiative constituted breach of contract by Boston Scientific.